Work

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.4506

Authors: Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Institutions: Sichuan University, West China Hospital of Sichuan University, 81th Hospital of PLA, Hunan Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, Second Affiliated Hospital of Anhui Medical University, First Affiliated Hospital of Bengbu Medical College, Zhejiang Cancer Hospital, Chinese PLA General Hospital, Fudan University Shanghai Cancer Center, Sir Run Run Shaw Hospital, Zhejiang University, Tang Du Hospital, Air Force Medical University, Chinese People's Liberation Army, Nantong Tumor Hospital, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (China), Nanjing Medical University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3029344012

Cites:

Cited by: 39

Related to: 10